Cell therapy manufacturing automation | Can automation deliver commercial scale?

Can automation truly deliver the scale that cell and gene therapy manufacturing needs? In this expert panel discussion, leaders from Johnson & Johnson, NYBC Ventures and Cellular Origins explore one of the biggest challenges facing the industry: how to expand manufacturing capacity without increasing complexity, compromising quality or forcing therapy developers to redesign their manufacturing process. The discussion covers: Why today's manufacturing approaches struggle to support commercial demand The role of automation in scaling cell and gene therapy manufacturing Balancing flexibility, cost of goods and manufacturing capacity Lessons learned from therapy developers and manufacturers How robotics and proven bioprocess technologies can work together What the future of industrialised cell therapy manufacturing could look like Panellists Edwin Stone, CEO, Cellular Origins (Moderator) John Knighton, Johnson & Johnson Meg Wood, NYBC Ventures Whether you're a cell therapy developer, CDMO, process development scientist or manufacturing leader, this webinar provides practical insights into the technologies and strategies shaping the future of advanced therapy manufacturing. Learn more about Cellular Origins: 🌐 https://cellularorigins.com Explore our latest insights: https://cellularorigins.com/thehub/ Follow Cellular Origins: LinkedIn: https://www.linkedin.com/company/cellularo... Keywords: cell therapy manufacturing, cell and gene therapy, CGT manufacturing, cell therapy automation, manufacturing automation, commercial scale manufacturing, autologous cell therapy, advanced therapies, robotics, bioprocessing, Johnson & Johnson, NYBC Ventures, Cellular Origins. #CellTherapy #CellTherapyManufacturing #CGT #CellTherapyAutomation #AdvancedTherapies #Bioprocessing #ManufacturingAutomation #Robotics #Commercialisation #Webinar